The company maintains a healthy liquidity position with $582.7 million in cash as of 2026Q1, though this is offset by a massive accumulated deficit in retained earnings of -$782.0 million.
| Total Current Assets | 594.31M | 660.78M | 221.34M | 144.7M | 22.65M | 56.64M | 42.89M | 3.12M | 2.11M |
| Cash & Short-Term Investments | 582.69M | 653.48M | 217.3M | 138.14M | 20.32M | 49.23M | 39.77M | 2.54M | 1.6M |
| Cash Only | 582.69M | 653.48M | 143.35M | 98.68M | 20.32M | 49.23M | 39.77M | 2.54M | 1.6M |
| Short-Term Investments | 0 | 0 | 73.95M | 39.46M | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 289K | 847K | 4.31M | 850K | 0 | 0 |
| Days Sales Outstanding | - | - | - | 7.53 | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 11.62M | 7.29M | 4.04M | 4.99M | 0 | 0 | 0 | 0 | 509K |
| Total Non-Current Assets | 25.48M | 22.41M | 18.9M | 3.84M | 1.4M | 1.29M | 1.63M | 1.94M | 2.34M |
| Property, Plant & Equipment | 19.91M | 17.61M | 14.39M | 3.64M | 965K | 855K | 1.53M | 1.7M | 2.08M |
| Fixed Asset Turnover | 0.24x | 0.39x | 0.63x | 3.85x | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 210K | 210K | 0 | 100K | 0 | 100K | 100K | 0 | 100K |
| Other Non-Current Assets | 5.57M | 4.59M | 4.51M | 100K | 432K | 332K | 0 | 238K | 155K |
| Total Assets | 619.79M | 683.19M | 240.24M | 148.54M | 24.05M | 57.92M | 44.52M | 5.06M | 4.45M |
| Asset Turnover | 0.01x | 0.01x | 0.04x | 0.09x | - | - | - | - | - |
| Asset Growth % | 281.8% | 184.38% | 61.73% | 517.73% | -58.49% | 30.1% | 779.94% | 13.76% | - |
| Total Current Liabilities | 27.41M | 44.99M | 54.31M | 21.83M | 7.33M | 9.73M | 3.04M | 1.67M | 1.56M |
| Accounts Payable | 5.53M | 3.34M | 14.19M | 3.31M | 2.4M | 3.08M | 1.19M | 548K | 473K |
| Days Payables Outstanding | 35.44 | 412.43 | - | - | - | - | 573.85 | 325.24 | 331.37 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 479K | 212K | 225K |
| Deferred Revenue (Current) | 0 | 0 | 6.94M | 10.49M | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 21.88M | 41.65M | 8M | 4.98M | 1.96M | 2.02M | 527K | 426K | 83K |
| Current Ratio | 21.68x | 14.69x | 4.08x | 6.63x | 3.09x | 5.82x | 14.12x | 1.88x | 1.35x |
| Quick Ratio | 21.68x | 14.69x | 4.08x | 6.63x | 3.09x | 5.82x | 14.12x | 1.88x | 1.35x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 3.69M | 3.85M | 4.77M | 6.83M | 62K | 12K | 142K | 39.02M | 28.09M |
| Long-Term Debt | 3.69M | 3.85M | 0 | 0 | 0 | 0 | 134K | 113K | 325K |
| Capital Lease Obligations | 4.14M | 0 | 4.77M | 1.34M | 62K | 0 | 0 | 0 | 239K |
| Deferred Tax Liabilities | 0 | 0 | 0 | -5.49M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 5.49M | 0 | 12K | 8K | 38.91M | 27.53M |
| Total Liabilities | 31.11M | 48.84M | 59.08M | 28.66M | 7.39M | 9.74M | 3.18M | 40.69M | 29.65M |
| Total Debt | 3.69M | 3.85M | 4.83M | 1.65M | 291K | 317K | 613K | 564K | 1.18M |
| Net Debt | -579M | -649.63M | -138.52M | -97.03M | -20.03M | -48.91M | -39.15M | -1.98M | -426K |
| Debt / Equity | 0.01x | 0.01x | 0.03x | 0.01x | 0.02x | 0.01x | 0.01x | - | - |
| Debt / EBITDA | -0.02x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 2.45x | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -7380.20x | -2520.40x | -468.37x | -97.53x | -54.64x |
| Total Equity | 588.69M | 634.34M | 181.16M | 119.88M | 16.65M | 48.19M | 41.34M | -35.63M | -25.2M |
| Equity Growth % | 370.71% | 250.15% | 51.12% | 619.88% | -65.44% | 16.54% | 216.04% | -41.36% | - |
| Book Value per Share | 5.20 | 7.26 | 3.09 | 6.04 | 1.37 | 4.18 | 4.09 | -6.20 | -23.07 |
| Total Shareholders' Equity | 588.69M | 634.34M | 181.16M | 119.88M | 16.65M | 48.19M | 41.34M | -35.63M | -25.2M |
| Common Stock | 11K | 11K | 6K | 4K | 1K | 1K | 1K | 0 | 1K |
| Retained Earnings | -782M | -728.16M | -515.77M | -222.81M | -116M | -79.11M | -54.39M | -36.56M | -26.11M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 57K | 22K | 0 | -57.92M | -44.52M | 0 | -904K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical Pipeline Execution Risk
According to recent balance sheet data, Immunome's total assets surged from $148.5 million in 2023Q4 to $619.8 million by 2026Q1, a trend driven primarily by external capital raises rather than organic growth, which effectively masks the underlying deterioration of the company's core operational sustainability.
The significant expansion in the asset base appears to be a strategic buffer intended to fund the transition toward an internal oncology development model. Investors should monitor whether this capital is deployed efficiently into clinical milestones or if it merely serves to offset the widening operating losses observed in recent periods.
As reported in financial statements, Immunome maintains a robust liquidity position with $582.7 million in cash and equivalents as of 2026Q1, providing a substantial buffer against the company's current cash-burning trajectory and reducing the immediate necessity for dilutive financing in the near term.
The current ratio of 21.68 suggests an exceptionally liquid position, which is typical for a biotech firm post-capital raise. However, this liquidity should be viewed as a finite resource that will be rapidly depleted as clinical trial costs for the oncology pipeline scale over the coming quarters.
Based on reported figures, Immunome's equity base has been significantly bolstered by capital raises, yet the persistent accumulation of retained earnings losses, which reached -$782.0 million in 2026Q1, indicates that shareholder value is being eroded by the high costs of maintaining its proprietary discovery platform.
The reliance on equity-based incentives to manage cash burn suggests that shareholders may face ongoing dilution risks. This structure warrants further investigation into whether the current management strategy can generate sufficient clinical value to offset the long-term impact of this equity-heavy compensation model.
While the balance sheet appears healthy due to high cash levels, the absence of deferred revenue, which dropped to zero in 2026Q1 from $16.0 million in 2023Q4, signals a complete loss of legacy collaboration-based income, leaving the company entirely dependent on its own clinical execution.
The shift away from partnership-driven revenue streams implies that the company has moved to a higher-risk, higher-reward model. Investors should be wary that the current asset mix is heavily skewed toward cash, which provides no inherent operational moat without successful clinical validation of the oncology pipeline.
Quick answers to the most common questions about buying IMNM stock.
As of 2025, Immunome, Inc. (IMNM) had total assets of $683.2M including $660.8M in current assets.
Immunome, Inc. (IMNM) carries total debt of $3.9M, offset by $653.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Immunome, Inc. (IMNM) has total shareholders' equity (book value) of $634.3M ($7.26 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Immunome, Inc. (IMNM) reported a current ratio of 14.69x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.